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There is increasing concern amongst clinicians of a possible increase in venous thromboembolism 
(VTE) events in patients with COVID-19. There remains limited data defining the incidence of VTE 
in this population and thus also a paucity of research examining the impact of targeted treatment 
in patients with thrombotic complications. 
 
Methods 
We examined the number of symptomatic VTE events amongst proven COVID-19 patients 
admitted to a tertiary level academic hospital, over a one-month period. Patient characteristics, 
admission and discharge inflammatory and coagulation markers were included in the analysis.  
 
Results 
Sixty-one patients were identified. Twelve patients (19.6%) admitted with COVID-19 were treated 
for a suspected PE. Of these patients, 3 patients were discharged on anticoagulation, 3 died and 
6 remain inpatients at the end of the study period. 
 
Discussion 
COVID-19 patients are at increased risk of VTE. This risk may extend beyond the period of 
admission. Further research examining the role of extending the duration of thromboprophylaxis 





There is increasing concern amongst clinicians of an increase in venous thromboembolism (VTE) 
events in patients with COVID-19, regardless of routine thromboprophylaxis practice.1,2 COVID-19 
promotes a pro-inflammatory and hypercoagulable state. Microvascular pulmonary thrombosis 
may play a role in the development of acute respiratory failure in this cohort.3 One recent study has 
shown a mortality benefit from anticoagulation in patients with severe COVID-19 or a markedly 
elevated D-Dimer.4  
However, there remains limited data defining the incidence of VTE in this population and thus also 






We examined the number of symptomatic VTE events amongst proven COVID-19 patients admitted 
to a tertiary level academic hospital, over a one-month period from 23rd March 2020 to 23rd April 
2020. Patient characteristics, admission and discharge inflammatory and coagulation markers were 





Sixty-one patients were identified, with a male predominance at 61%. All were commenced on 
thromboprophylaxis on admission. The median age (range) was 65 (25-89) years. On admission, D-
Dimer and fibrinogen count was carried out in 60 and 47 patients respectively. In these patients, D-
Dimer level was elevated in 68% (median 0.68mg/L FEU; Normal hospital range:0-0.5mg/L FEU) and 
fibrinogen level elevated in 83% (median 5.7; Normal hospital range:1.7-4.1g/L).  
 
Of this cohort, anticoagulation was empirically commenced (weight based therapeutic tinzaparin) 
in patients with a high clinical suspicion of pulmonary embolus (PE). Acute PE was confirmed by 
computed tomography pulmonary angiogram (CTPA) in 4 patients (6.6%). A further 8 patients were 
deemed to have a high probability of PE based on the treating physician’s assessment of the 
patient’s acute deterioration in respiratory or hemodynamic status as well as elevated D-Dimer and 
troponin levels. BNP levels were not routinely measured. Diagnostic imaging was not feasible in 
these 8 patients due to clinical instability. Of these 8 patients, 38% (3/8) had an elevated troponin 
level at time of acute deterioration. The median (range) admission D-dimer in this treated cohort of 
patients was 2.7(0.31-16.7) mg/L FEU.  
 
Hence, within our institution, 19.6% (12/61) of patients admitted with COVID-19 were treated for a 
suspected PE. Of these 12 patients, at the end of the month study period, 25% (3/12) patients were 
discharged on anticoagulation, 25% (3/12) died and 50% (6/12) remain inpatients. Post-mortem 
studies were not carried out on the deceased. 
 
Of our total cohort of 61 patients, 49% (30/61) were discharged and on discharge, 30% (9/30) had 
a raised D-Dimer level. Excluding the 33% (3/9) of patients who were treated for VTE during their 
inpatient stay and were discharged on anti-coagulation, there were a further 67% (6/9) patients 
with elevated D-Dimers on discharge. One patient was on anti-coagulation for a pre-existing cardiac 
condition pre-admission. The remaining 56% (5/9) patients with elevated D-Dimers on discharge 





There is an emerging concept of pulmonary intravascular coagulopathy in patients with COVID-19.1 
In our study, 19.6% of all patients admitted with COVID-19 were treated for an acute PE. This would 
appear to represent a significantly increased risk, given that in critically ill patients without a 
diagnosis of COVID-19, the reported rate of PE is 1.3%.5  
Of the patients diagnosed with co-existing PE and COVID-19, 3 patients died, 2 are currently 
intubated in intensive care and a further 4 remain inpatients. The median admission D-Dimer in 
these patients was 2.7mg/L FEU. Elevated D-Dimer levels have been linked with disease progression 
and an increased mortality rate in hospitalised COVID-19 patients.6 Our findings would support this 
data. 
 
Many organisations have advocated for more aggressive thromboprophylaxis regimens.7 The 
American College of Chest Physicians guidelines currently recommend against extending the 
duration of thrombophylaxis beyond the period of acute hospital stay as this did not result in 
reduced VTE rates.8 However, further studies have shown that high risk patients such as those with 
high D Dimers did benefit.9 A statement endorsed by several international expert bodies, has stated 
that ‘while no data specific to COVID-19 exist, it is reasonable to employ individualized risk 
stratification for thrombotic and haemorrhagic risk, followed by consideration of extended 
prophylaxis (for up to 45 days)’.10 Given the high proportion of our cohort with elevated D-Dimers 
on discharge, the potential high risk of VTE events and functional limitation, extended 
thrombophylaxis post hospital stay in this group may be a consideration. 
 
Therefore, we believe that COVID patients are at increased risk of VTE and that this risk may extend 
beyond the period of admission. Further research, including the enrollment of suitable patients in a 
clinical trial and, at local level, the engagement of multidisciplinary specialists in decision-making 




BNP: Brain natriuretic peptide 
CTPA: Computed tomography pulmonary angiogram  
FEU: Fibrinogen-equivalent-units 
PE: Pulmonary Embolus 
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